MedTrace Logo

A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects

NCT06846684 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-11-19

No results posted yet for this study

Summary

This clinical trial is a phase 1, open-label, fixed-sequence, drug-drug interaction study to investigate the effect of single and multiple oral doses of SB17170 on the pharmacokinetics of SB\_MDZ in healthy adult subjects.

Conditions

  • Drug Drug Interaction (DDI)

Interventions

DRUG

SB17170

PO, QD

DRUG

SB_MDZ

IV

Sponsors & Collaborators

  • SPARK Biopharma

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-27
Primary Completion
2025-06-10
Completion
2025-09-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06846684 on ClinicalTrials.gov